Literature DB >> 3556376

Pharmacokinetics of doxorubicin in sarcoma patients.

J Robert, N B Bui, P Vrignaud.   

Abstract

The pharmacokinetics of doxorubicin has been studied in 26 sarcoma patients receiving polychemotherapy. Mean elimination half-life was 34.7 +/- 16.6 h and the total plasma clearance was 29.5 +/- 9.31 X h-1 X m-2. No relationship was found between the pharmacokinetic parameters and the response to treatment, or its toxicity. Special attention was paid to the early-phase kinetics of the drug (3-20 min after injection). A correlation between the early clearance and the ages of the patients was observed. The early clearance was clearly correlated with the total plasma clearance measured over 48 h after injection, indicating the importance of the distribution phase in the overall kinetics of the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3556376     DOI: 10.1007/BF00541297

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Early-phase pharmacokinetics of doxorubicin in non-Hodgkin lymphoma patients. Dose-dependent and time-dependent pharmacokinetic parameters.

Authors:  J Robert; B Hoerni; P Vrignaud; C Lagarde
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

2.  Age dependence of the early-phase pharmacokinetics of doxorubicin.

Authors:  J Robert; B Hoerni
Journal:  Cancer Res       Date:  1983-09       Impact factor: 12.701

3.  Tentative dose-monitoring of doxorubicin in lymphoma patients.

Authors:  J Robert; P Vrignaud; H Eghbali; T Nguyen-Ngoc; B Hoerni
Journal:  Med Oncol Tumor Pharmacother       Date:  1985

4.  Analysis of a series of sixty soft tissue sarcomas in adults treated with a cyclophosphamide-vincristine-adriamycin-dacarbazine (CYVADIC) combination.

Authors:  N B Bui; J Chauvergne; C Hocke; M Durand; R Brunet; J M Coindre
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system.

Authors:  M Trojani; G Contesso; J M Coindre; J Rouesse; N B Bui; A de Mascarel; J F Goussot; M David; F Bonichon; C Lagarde
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

6.  Cellular pharmacology of doxorubicin in sensitive and resistant rat glioblastoma cells in culture.

Authors:  P Vrignaud; D Londos-Gagliardi; J Robert
Journal:  Oncology       Date:  1986       Impact factor: 2.935

7.  [Pharmacokinetic study of doxorubicin in the treatment of malignant non-Hodgkin's lymphomas].

Authors:  J Robert; P Vrignaud; A Iliadis; H Eghbali; B Hoerni
Journal:  Nouv Rev Fr Hematol       Date:  1983

8.  Time dependency of adriamycin and adriamycinol kinetics.

Authors:  P Gil; R Favre; A Durand; A Iliadis; J P Cano; Y Carcassonne
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

10.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

View more
  13 in total

1.  Simulation of the delivery of doxorubicin to hepatoma.

Authors:  Y M Goh; H L Kong; C H Wang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters.

Authors:  J M Jacquet; F Bressolle; M Galtier; M Bourrier; D Donadio; J Jourdan; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.

Authors:  Swantje Völler; Joachim Boos; Miriam Krischke; Gudrun Würthwein; Nina E Kontny; Alan V Boddy; Georg Hempel
Journal:  Clin Pharmacokinet       Date:  2015-11       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of breast cancer.

Authors:  V J Wiebe; C C Benz; M W DeGregorio
Journal:  Clin Pharmacokinet       Date:  1988-09       Impact factor: 6.447

5.  Phase I and pharmacokinetic study of the novel anthracycline derivative 5-imino-13-deoxydoxorubicin (GPX-150) in patients with advanced solid tumors.

Authors:  Sarah A Holstein; James C Bigelow; Richard D Olson; Robert E Vestal; Gerald M Walsh; Raymond J Hohl
Journal:  Invest New Drugs       Date:  2015-02-21       Impact factor: 3.850

6.  Doxorubicin and doxorubicinol plasma concentrations and excretion in parotid saliva.

Authors:  F Bressolle; J M Jacquet; M Galtier; J Jourdan; D Donadio; J F Rossi
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

7.  Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.

Authors:  Jonás Samuel Pérez-Blanco; Dolores Santos-Buelga; María Del Mar Fernández de Gatta; Jesús María Hernández-Rivas; Alejandro Martín; María José García
Journal:  Br J Clin Pharmacol       Date:  2016-09-06       Impact factor: 4.335

8.  Pharmacokinetics of doxorubicin in pregnant women.

Authors:  Rachel J Ryu; Sara Eyal; Henry G Kaplan; Arezoo Akbarzadeh; Karen Hays; Kristin Puhl; Thomas R Easterling; Stacey L Berg; Kathleen A Scorsone; Eric M Feldman; Jason G Umans; Menachem Miodovnik; Mary F Hebert
Journal:  Cancer Chemother Pharmacol       Date:  2014-02-15       Impact factor: 3.333

9.  A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.

Authors:  J Robert; A Monnier; N Poutignat; P Hérait
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.

Authors:  Jason T Anderson; Kevin M Huang; Maryam B Lustberg; Alex Sparreboom; Shuiying Hu
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 7.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.